About the GVDNThe GVDN facilitates globally coordinated vaccine safety monitoring
The Global Vaccine Data Network (GVDN) is an international consortium for vaccine safety research that currently consists of 22 partners in 18 countries.
The GVDN seeks to address the following limitations:
- Scope of data to properly understand and demonstrate vaccine risk vs benefit in different populations and individuals
- Lack of infrastructure and capabilities to monitor and evaluate vaccine outcomes in low to middle income countries
- Delays in collating vaccine usage data to inform decisions during global pandemic events
- Readily accessible, evidence-based material for use in communications
Uncommon Adverse Events Following Immunization (AEFI) can only be evaluated in post-introduction pharmacovigilance (PIPV) studies. The Global Vaccine Data Network makes it possible to perform global collaborative retrospective analyses of health data utilising the existing capabilities of some partners, while growing the capacity of countries with less developed data infrastructures. This includes rapid-cycle analyses. Sharing of standards and common data protocols facilitates robust and rapid scientific outputs that contribute strong evidence to the dialogue around vaccine use and safety. The global scale provides even greater precision in understanding vaccine outcomes. Furthermore, development of data capabilities designed to explore more individualised aspects of vaccine safety may help to ascertain the genomic basis for variability in response to vaccines.
Recently the use of large administrative databases that contain interactions with health services has become easier. Vaccine safety research relies on being able to identify the exposure to a vaccine. Rare events that may be associated with vaccines need very large populations because:
- Serious adverse events are very rare
- There is wide variability in the types and manufactures of vaccines used in different countries
- We need to explore the risk in subgroups such as older people and children.
The first study planned by the GVDN will cover an underlying population of almost 2 billion person-years.
How can big data help assess vaccines
- Collections of routinely collected health data already exist in many countries. These collections are diverse, containing useful information such as hospitalisations, pharmaceuticals including vaccines, pregnancy and birth over time.
- Collaborations between organisations holding different data within a country, for example, the Vaccine Safety Datalink, or across countries within a continent such as VAC4EU, are examples of the successful use of this data for meaningful advances in the knowledge of vaccine safety and effectiveness as well as vaccination coverage and cost effectiveness.
- Randomised controlled trials (RCT) are usually used to assess vaccine safety and efficacy. However compared to RCTs, big data can provide a picture of vaccine safety and effectiveness across large and diverse groups of people and over time. This is because some groups of people are usually left out of prelicensure trials. For example, people with particular health conditions, ethnic minority groups and pregnant women. Additionally, big data can capture information over longer periods of time than RCTs. These features of big data mean identifying rare events and longer term effects is possible.
Unfortunately, in the last decade we have also seen the proliferation of vaccine safety scares promulgated widely through the internet and social media. Several such scares have derailed the polio vaccination program and other important vaccination programs including measles vaccination in the UK and HPV vaccination in Japan. Safety concerns, whether real or perceived, can spread beyond borders and severely interrupt successful vaccination programs. While vaccine hesitancy and anti-vaccine communication have become global, the ability to respond to such concerns has remained largely fractured without coordination between countries. With the advent of large clinical databases in many countries of the world and multi-country collaborations, it is now possible to standardize approaches and rapidly evaluate rare vaccine safety concerns through initiatives such as the Global Vaccine Data Network.
The last ten years has seen a dramatic expansion of the number of vaccines in use globally and in the number of manufacturers involved in the global vaccine marketplace. This expansion has had a tremendous positive impact on the health of the world’s population. The continued success of the global vaccination effort relies upon the use of safe vaccines and public confidence in both their utility and safety. For thorough and authoritative information about vaccine safety, including the immune system, different vaccine examples, vaccine doses and ingredients, and chronic conditions that some people link to vaccination, please visit the website of the Children’s Hospital of Philadelphia.
Disclaimer: Links to third party content are provided here as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by the GVDN. The GVDN bears no responsibility for the accuracy, legality or content of the third party site or for that of subsequent links. Please contact the third party site for answers to questions regarding its content.
The intended audience for this website are:
- Researchers who are cooperating on studies, exploring collaborations, or looking for peer reviewers
- Researchers working in the vaccine/pharmacovigilance space
- Global health agencies, global non-profit alliances, national health bodies
- Countries looking at the infrastructure needed to monitor vaccine effectiveness and safety
- A broad public audience (e.g. those interested in how COVID-19 vaccine safety is being monitored)
- Others interested in vaccines and vaccine safety issues.
The GVDN works closely with vaccine safety experts around the world, global health agencies, and other global non-profit health alliances. The GVDN received seeding money from the Gates foundation, enjoys support in kind from Auckland UniServices, and relies on research grants for specific vaccine safety monitoring projects. Auckland UniServices Limited is a wholly owned non-profit subsidiary of The University of Auckland, which has been ranked #1 for two consecutive years in the Impact rankings by Times Higher Education (THE).
The Global Vaccine Data Network is a non-profit organisation supported by a Scientific Advisory Committee. Our website is maintained by the Secretariat of the GVDN, which is based at The University of Auckland in New Zealand. Website content is developed by the Secretariat and then reviewed by team members and one of the GVDN’s two co-directors. GVDN partners have all demonstrated experience in using administrative data to assess vaccines. The GVDN’s two co-directors are Helen Petousis-Harris, a vaccinologist and associate professor in the Department of General Practice and Primary Health Care at The University of Auckland and Director of the Vaccine Datalink and Research Group, and Steve Black, work package lead for Safety Platform for Emergency vACcines (SPEAC), Emeritus Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center, Consulting Professor of Epidemiology, Fudan University in Shanghai, and Editor-in-Chief of the Pediatric Infectious Disease Journal.
In April 2021, the GVDN received significant funding from the US Centers for Disease Control and Prevention for a 3 year project entitled Global Covid Vaccine Safety (GCoVS). The purpose of this project is to put in place a coordinated and harmonized post-introduction active surveillance infrastructure in diverse populations across the globe to assess the safety of COVID-19 vaccines. This infrastructure will be capable of responding to safety signals post-introduction of COVID-19 vaccines.